Premium
Medical management of diabetic retinopathy
Author(s) -
Sjølie A. K.,
Møller F.
Publication year - 2004
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1111/j.1464-5491.2004.01208.x
Subject(s) - medicine , diabetic retinopathy , retinopathy , diabetes mellitus , clinical trial , intensive care medicine , pharmacology , endocrinology
Although current treatment and prevention of diabetic retinopathy with laser photocoagulation, and tight metabolic and blood pressure control has reduced the risk of visual loss, there is still a need for additional therapies. A literature review on medical therapies for diabetic retinopathy has been performed, and the following classes of drugs are discussed: blockers of the renin–angiotensin system, protein kinase C‐β inhibitors, glitazones, somatostatin analogues, lipid‐lowering drugs and anti‐inflammatory drugs. There is experimental and clinical data suggesting beneficial effect from several classes of drugs on diabetic retinopathy, and results from large clinical trials are awaited within the next 3–4 years.